Real world effects of medications for chronic obstructive pulmonary disease

The effects of medications for chronic obstructive pulmonary disease on mortality, pneumonia and exacerbation rate amongst UK patients with COPD

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN73872958

Enrollment

6000

Registered

2016-12-05

Start date

2017-05-01

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease (COPD) Respiratory Chronic obstructive pulmonary disease (COPD)

Interventions

Electronic patient medical records will be searched for prescriptions of study medication, as issued under routine clinical care. Based on these records patients will then be assigned to appropriate t

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: For the primary analysis, the following inclusion criteria will apply: 1. A diagnosis of COPD, 2. Age 40-80 years, 3. Lung function (FEV180 years, OR 2. History of lung surgery OR 3. History of long term oxygen therapy OR 4. Evidence of drug/alcohol abuse OR 5. Substantial comorbidity For the analysis of people with mild COPD, the following criteria will apply: 1. COPD diagnosis 2. >60% predicted FEV1 (or >50% plus MRC score 1 or 2, or >50% plus CAT score <10) 3. A maximum of 1 exacerbation in the year post COPD diagnosis

Exclusion criteria

Exclusion criteria: For the primary analysis closely mirroring the TORCH study, exclusions are: 1. History of asthma 2. History of lung surgery 3. Requirement for long-term oxygen therapy 4. Diagnosed alpha-1 antitrypsin deficiency 5. Evidence of drug/alcohol abuse For the secondary anlayses: There are no exclusion criteria.

Design outcomes

Primary

Measure	Time frame
1. COPD exacerbation rate will be determined using primary care electronic health records and linked hospital records, within three years of starting treatment 2. Mortality rate will be determined using primary care electronic health records and linked hospital records and linked office for national statistics mortality records, within three years of starting treatment 3. Pneumonia rate will be determined using primary care electronic health records and linked hospital records, within three years of starting treatment	—

Measure

Time frame

1. COPD exacerbation rate will be determined using primary care electronic health records and linked hospital records, within three years of starting treatment 2. Mortality rate will be determined using primary care electronic health records and linked hospital records and linked office for national statistics mortality records, within three years of starting treatment 3. Pneumonia rate will be determined using primary care electronic health records and linked hospital records, within three years of starting treatment

—

Secondary

Measure	Time frame
Time to change in treatment for COPD will be determined using primary care electronic health records within three years of starting treatment	—

Countries

England, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026